Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase. clinical trial.

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd